Decoration of Hcp1 protein to virus-like particles as a vaccine delivery platform

Nittaya Khakhum,Noe Baruch-Torres,Jacob L. Stockton,Itziar Chapartegui-González,Alexander J Badten,Awadalkareem Adam,Tian Wang,Alejandro Huerta-Saquero,Y. Whitney Yin,Alfredo G Torres

DOI: https://doi.org/10.1101/2024.01.17.576127

2024-01-18

Abstract:Virus-like particles (VLPs) are protein-based nanoparticles frequently used as carrier in conjugate vaccine platforms. VLPs have been used to display foreign antigens for vaccination and to deliver immunotherapeutic against diseases. Hemolysin-coregulated proteins 1 (Hcp1) is a protein component of the type 6 secretion system which participates in intracellular invasion and dissemination. This protein has been reported as a protective antigen and is used in multiple vaccine candidates with various platforms against melioidosis, a severe infectious disease caused by the intracellular pathogen . In this study, we used P22 VLPs as a surface platform for decoration with Hcp1 using chemical conjugation. C57BL/6 mice were intranasally immunized with three doses of either PBS, VLPs or conjugated Hcp1-VLPs. Immunization with Hcp1-VLPs formulation induced Hcp1-specific-IgG, IgG , IgG and IgA antibody responses. Furthermore, the serum from Hcp1-VLPs immunized mice enhanced the bacterial uptake and opsonophagocytosis by macrophages in the presence of complement. This study demonstrated an alternative strategy to develop a VLPs-based vaccine platform against species.

Microbiology

What problem does this paper attempt to address?

This paper mainly discusses how to use virus-like particles (VLPs) as carriers to display Hemolysin co-regulated protein 1 (Hcp1) to develop nano-vaccines against Burkholderia species. Burkholderia species is an intracellular pathogen that causes severe infectious disease melioidosis. The researchers attached the Hcp1 protein to the surface of P22 VLPs using chemical conjugation methods to construct the Hcp1-VLP nano-vaccine.

The experimental results showed that after intranasal immunization in mice, the Hcp1-VLP vaccine could induce the production of specific antibodies (including IgG, IgG1, and IgA) and enhance the phagocytic activity of macrophages against bacteria. This indicates that this vaccine strategy may effectively combat Burkholderia species infection.

The paper also details the expression and purification of Hcp1 protein, the production and purification of P22 VLPs, and the chemical conjugation process of Hcp1 and VLPs. Transmission electron microscopy analysis confirmed the successful binding of Hcp1 to the surface of VLPs. The serum produced by immunized mice enhanced the phagocytic activity against Burkholderia species, which depended on the presence of complement.

In conclusion, this study proposes a novel VLPs vaccine platform for combating Burkholderia species infection, demonstrates the potential of Hcp1 protein as a protective antigen, and proves the effectiveness of chemical conjugation methods in constructing nano-vaccines.